Key PointsPfizer's numbers were strong in its most recent quarter, with both its top and bottom lines coming in better than analyst forecasts.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.